Q-omics provides the consensus-scored LINC02163 profile across patient tissues and cancer cell-line models. LINC02163 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02163 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, LINC02163 RNA expression shows 11,103 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where LINC02163 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02163 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02163 survival associations across molecular data types. LINC02163 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02163 RNA expression–survival associations across cancer types. High LINC02163 expression shows unfavorable associations in KIRC, KIRP, UVM, DLBC and LGG, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02163 RNA expression.
This table summarizes LINC02163 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02163. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02163 shows higher tumor expression in COAD, HNSC, LUSC, BLCA, STAD and LIHC. The COAD box plot shows higher LINC02163 RNA expression in tumor versus normal tissue (log2 FC = +1.984, t-test p < 0.001).
This table shows molecular features associated with LINC02163 in patient tissues and cancer cell lines. In patient samples, LINC02163 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
